Company intelligence / Profile preview
Asceneuron SA
Lausanne, Switzerlandasceneuron.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Asceneuron has completed five Phase I clinical trials with its lead OGA inhibitor ASN51, demonstrating full central nervous system uptake and high target engagement. ASN51 will enter its first Phase II trial for Alzheimer’s disease in the second half of 2024. Another OGA inhibitor, ASN90, was licensed to Ferrer Pharmaceuticals for progressive supranuclear palsy. The company also has preclinical programs targeting Parkinson’s and ALS[2][6][7].
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Ferrer PharmaceuticalsCritical Path Institute – CPAD Consortium
Beyond the preview
Go deeper on Asceneuron SA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asceneuron SA.